Astellas seeks conditional approval for GA treatment in Japan
Astellas Pharma has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare seeking conditional approval …
Astellas Pharma has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare seeking conditional approval …
The last few days have been a rollercoaster for the pharmaceutical industry. Mexico and Canada were bracing themselves for the …
During the 43rd J.P. Morgan Annual Healthcare Conference last month, Areteia Therapeutics took centre stage, presenting a detailed review of …
MedPharm has appointed Bill Humphries as its new CEO, marking a significant step in the company's strategic growth. The move follows …
Jabil has acquired contract development and manufacturing organisation (CDMO) Pharmaceutics International (Pii) to offer support for drug development customers. The acquisition …
A reinvigorated interest in radiopharmaceuticals has brought nuclear medicine to the foreground with deals over 2024 further exemplifying this trend. As …
Italian research charity Telethon Foundation is one step closer to getting a gene therapy to treat rare disease Wiskott-Aldrich syndrome …
Thermo Fisher is cutting the headcount at two of its US facilities by 300 as the company continues to overhaul …
The University of Southern California (USC) has received a $6m grant from the California Institute for Regenerative Medicine (CIRM) to …
Immunotherapeutics have transformed the landscape of cancer outcomes. It is crucial that the atypical response patterns seen with them are …
The World Health Organization (WHO) has reported a significant increase in cancer cases across the Southeast Asia region, projecting an …
Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4 …
Microplastics, tiny plastic bits less than five millimetres in size, come from breaking down larger plastics and are now everywhere. …
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi (durvalumab) for approval in the …
Access to high-quality cancer care remains deeply uneven worldwide. While advances in cancer treatment and diagnostics are improving survival rates …